Follow this link:
CarnoSyn® Brands Announces New U.S. Distribution Agreement With B&D Nutritional Ingredients
Related Post
- Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD - October 30th, 2024
- Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity - October 30th, 2024
- Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile - October 30th, 2024
- Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update - October 30th, 2024
- Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company - October 30th, 2024
- BioVie Inc. Announces Closing of Registered Direct Offering - October 30th, 2024
- Shuttle Pharma Pays Off Senior Secured Convertible Note - October 30th, 2024
- ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024 - October 30th, 2024
- Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024 - October 30th, 2024
- Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast - October 30th, 2024
- Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024 - October 30th, 2024
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 - October 30th, 2024
- MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call - October 30th, 2024
- Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call - October 30th, 2024
- Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET - October 30th, 2024
- Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights - October 30th, 2024
- Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - October 30th, 2024
- Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and... - October 30th, 2024
- BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split - October 30th, 2024
- Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend - October 30th, 2024
- Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies - October 27th, 2024
- INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination - October 27th, 2024
- Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week - October 27th, 2024
- BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement - October 27th, 2024
- Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting - October 27th, 2024
- Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma - October 27th, 2024
- Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong... - October 27th, 2024
- Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference - October 27th, 2024
- Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 - October 27th, 2024
- Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN - October 27th, 2024
- Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN... - October 27th, 2024
- Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic... - October 27th, 2024
- Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 - October 27th, 2024
- Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial - October 27th, 2024
- Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart... - October 27th, 2024
- Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting - October 27th, 2024
- ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024 - October 25th, 2024
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06% - October 25th, 2024
- Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast - October 25th, 2024
- Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR... - October 25th, 2024
- Senseonics Holdings, Inc. Announces $16 Million Registered Direct Offering - October 25th, 2024
- Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and... - October 25th, 2024
- Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024 - October 25th, 2024
- Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - October 25th, 2024
- Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference - October 25th, 2024
- Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI... - October 25th, 2024
- Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - October 25th, 2024
- Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference - October 25th, 2024
- Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial... - October 25th, 2024
- Quality Smart Solutions Launches GRAS Experts to Protect Against Food Safety Risks - October 25th, 2024
- Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv - October 25th, 2024
- Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024... - October 25th, 2024
- Helio Genomics and Halub Medical Co. Announce Strategic Partnership to Commercialize HelioLiver Dx in The Gulf Cooperation Council and Middle East - October 25th, 2024
- ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - October 25th, 2024
- Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - October 25th, 2024
- Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas - October 25th, 2024
- New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024 - October 24th, 2024
- Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - October 24th, 2024
- Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function... - October 24th, 2024
- VIVUS Announces Label Update for QSYMIA® - October 24th, 2024
- Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference - October 24th, 2024
- Rapafusyn Announces an Upcoming Oral Presentation at Targeted Protein Degradation & Induced Proximity Summit - October 24th, 2024
- Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - October 24th, 2024
- Ancilia Biosciences Selected to Receive $3 Million Award from ARPA-H’s Sprint for Women’s Health - October 24th, 2024
- Orchard Therapeutics Announces Multiple Data Presentations and Publications - October 24th, 2024
- Spectral AI Schedules 2024 Third Quarter Financial Results and Conference Call - October 24th, 2024
- Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference - October 24th, 2024
- FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent - October 24th, 2024
- MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast... - October 24th, 2024
- argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 - October 24th, 2024
- Pharming Group reports third quarter 2024 financial results and provides business update - October 24th, 2024
- PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes - October 24th, 2024
- Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology... - October 24th, 2024
- Medigene AG reports Financial Results and Business Update for Q3 2024 - October 24th, 2024
- Rentschler Biopharma announces largest single investment at its headquarters in Germany - October 24th, 2024
- Vistin Pharma ASA: Invitation to Q3 2024 conference call - October 24th, 2024
- Innocan Pharma to Present at the 2024 ThinkEquity Conference - October 22nd, 2024
- Valneva to Present on Chikungunya at Several Leading Scientific Conferences - October 22nd, 2024
- Responsibility statement for first half year of 2024 - October 22nd, 2024
- Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days - October 22nd, 2024
Recent Comments